129
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Pristimerin attenuates ovalbumin-induced allergic airway inflammation in mice

, , , , &
Pages 221-227 | Received 19 Dec 2015, Accepted 16 Mar 2016, Published online: 21 Apr 2016
 

Abstract

Pristimerin has been shown to possess antiinflammatory activity. However, its potential use for asthma induced by airway inflammation has not yet been studied. First, we established a ovalbumin (OVA)-induced allergic asthma mice model. BALB/c mice were immunized and challenged by OVA. Treatment with pristimerin caused a marked reduction in the levels of OVA-specific IgE, immune cells, and IL-4, IL-5, IL-13 secretion. Histological studies using H&E staining were used to study the alterations in lung tissue. These results were similar to those obtained with dexamethasone treatment. We then investigated which signal transduction mechanisms could be implicated in pristimerin activity by Western blot. The data showed that pristimerin could inhibit MAPKs and NF-κB inflammatory pathways.

Disclosure statement

The authors report no declaration of interest.

Funding information

This work was financially supported by the 2015 Scientific Research Program of 12th Five Year Plan from the Education Department of Jilin Province (No. 2015-534 and No. 2016-489) and the Science and Technology Project from the Administration of Traditional Chinese Medicine of Jilin Province (No. 2012-147).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.